Get the Stockscreener App
2.295
6.74%
0.145
Autolus Therapeutics Plc Adr stock is traded at $2.295, with a volume of 2.45M.
It is up +6.74% in the last 24 hours and up +59.38% over the past month.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
See More
Previous Close:
$2.15
Open:
$2.15
24h Volume:
2.45M
Relative Volume:
1.37
Market Cap:
$611.81M
Revenue:
$92.67M
Net Income/Loss:
$-288.81M
P/E Ratio:
-2.1148
EPS:
-1.0852
Net Cash Flow:
$-295.51M
1W Performance:
+10.87%
1M Performance:
+59.38%
6M Performance:
+51.99%
1Y Performance:
+28.93%
1-Day Range:
$2.13
$2.33
1-Week Range:
$2.02
$2.43
52-Week Range:
$1.175
$2.43
Autolus Therapeutics Plc Adr Stock (AUTL) Company Profile
Name
Autolus Therapeutics Plc Adr
Sector
Industry
Phone
44 20 3829 6230
Address
THE MEDIAWORKS, LONDON
Compare AUTL vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUTL
Autolus Therapeutics Plc Adr
|
2.2988 | 572.21M | 92.67M | -288.81M | -295.51M | -1.0852 |
VRTX
Vertex Pharmaceuticals Inc
|
515.76 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.53 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.93 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.63 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Autolus Therapeutics Plc Adr Stock (AUTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-26 | Initiated | H.C. Wainwright | Buy |
| Nov-18-24 | Upgrade | Goldman | Neutral → Buy |
| Nov-15-24 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Mar-27-23 | Resumed | Wells Fargo | Overweight |
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| Jun-14-21 | Upgrade | Jefferies | Hold → Buy |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | JP Morgan | Overweight |
| Jul-22-20 | Initiated | SunTrust | Buy |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Sep-23-19 | Initiated | Needham | Buy |
| May-17-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-24-18 | Initiated | H.C. Wainwright | Buy |
View All
Autolus Therapeutics Plc Adr Stock (AUTL) Latest News
Syncona Portfolio Ltd Buys Shares of 16,640,720 Autolus Therapeutics PLC Sponsored ADR $AUTL - marketbeat.com
Autolus Therapeutics plc (AUTL) Stock Price, News, Quote & History - Yahoo Finance
Autolus Therapeutics (NASDAQ:AUTL) Trading Down 7%Here's Why - MarketBeat
Autolus Therapeutics (NASDAQ:AUTL) Trading 13.3% Higher Following Strong Earnings - MarketBeat
Renaissance Technologies LLC Has $3.17 Million Position in Autolus Therapeutics PLC Sponsored ADR $AUTL - marketbeat.com
Autolus Therapeutics (NASDAQ:AUTL) Shares Gap UpStill a Buy? - marketbeat.com
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Rating of "Moderate Buy" by Brokerages - marketbeat.com
Autolus Therapeutics (NASDAQ:AUTL) Trading Down 0.7%Time to Sell? - marketbeat.com
AUTLAutolus Therapeutics plc ADR Options - Finviz
Autolus Therapeutics Plc Sponsored ADR Actuals & Estimates (NASDAQ:AUTL) - TradingView
Enterprise value to revenue forward of Autolus Therapeutics Plc Sponsored ADR – TRADEGATE:6A3A - TradingView
Price to book forward of Autolus Therapeutics Plc Sponsored ADR – TRADEGATE:6A3A - TradingView
Price to sales forward of Autolus Therapeutics Plc Sponsored ADR – TRADEGATE:6A3A - TradingView
Price to earnings forward of Autolus Therapeutics Plc Sponsored ADR – TRADEGATE:6A3A - TradingView
Enterprise value to EBITDA forward of Autolus Therapeutics Plc Sponsored ADR – TRADEGATE:6A3A - TradingView
Autolus Therapeutics (AUTL) could find a support soon, here's why you should buy the stock now - MSN
Autolus Therapeutics Receives Prix Galien UK Award - GlobeNewswire Inc.
Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy? - sharewise.com
Apellis Pharmaceuticals (APLS) moves 135.4% higher: Will this strength last? - MSN
Autolus Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
Autolus Therapeutics (NASDAQ: AUTL) to cut 13% of staff, save $15M - Stock Titan
Autolus Therapeutics Eyes CAR-T Edge With AUCATZYL Safety, Expands Centers, Sees Margin Turnaround - Yahoo Finance
Autolus Therapeutics (NASDAQ: AUTL) registers $150M shelf for shares, ADSs, debt - Stock Titan
Autolus Therapeutics Highlights obe-cel Momentum in ALL With New Real-World ROKA and Pediatric Data - Yahoo Finance
Apellis Pharmaceuticals (APLS) Surges 135.4%: Can This Momentum Be Sustained? - Bitget
Apellis Pharmaceuticals (APLS) Moves 135.4% Higher: Will This Strength Last? - Yahoo Finance
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives $8.50 Consensus Target Price from Analysts - Defense World
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Autolus Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Mak Capital One LLC Buys 9,062,518 Shares of Autolus Therapeutics PLC Sponsored ADR $AUTL - MarketBeat
Autolus Therapeutics Touts $75M Year-1 Obe-cel Launch, Sees $120M-$135M Revenue in 2026 - Yahoo Finance
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
What is HC Wainwright’s Estimate for AUTL FY2025 Earnings? - Defense World
Q1 Earnings Forecast for AUTL Issued By HC Wainwright - MarketBeat
What is HC Wainwright's Estimate for AUTL FY2025 Earnings? - MarketBeat
New Strong Sell Stocks for January 30th - Yahoo Finance
New Strong Sell Stocks for January 22nd - Yahoo Finance
Why Gelteq Shares Are Trading Higher By 50%; Here Are 20 Stocks Moving Premarket - Benzinga
Truist Securities lowers Autolus Therapeutics stock price target on soft guidance - Investing.com
Autolus Therapeutics stock jumps after Needham raises price target - Investing.com
Is Autolus Therapeutics plc (AUTL) The Best Get Rich Fast Stocks to Buy Right Now? - finviz.com
Ryan Richardson joins Autolus Therapeutics board of directors - Investing.com
Autolus Therapeutics plc (AUTL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates? - Yahoo Finance
Needham Keeps Buy Rating on Autolus (AUTL) with a $10 Target - Finviz
Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy’ Ratings - Barchart.com
Gil Blum Analyst Performance at Needham & Company LLC - MarketBeat
Invesco Nasdaq Biotechnology ETF Holdings - Quiver Quantitative
Why Autolus Therapeutics plc (AUTL) is the Penny Stock with the Biggest Upside Potential According to Analysts - Yahoo Finance
AUTL Stock Price and Chart — NASDAQ:AUTL - TradingView
Autolus Therapeutics Plc Adr Stock (AUTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.24%
1.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):